ARTICLE | Clinical News
Cubist completes second Cidecin Phase III
July 16, 2001 7:00 AM UTC
CBST completed enrollment in a second Phase III study of its Cidecin daptomycin to treat complicated skin and soft tissue infections (cSST). The primary end point of the U.S. study, which is designed ...